UNSPSC 51161569: Montelukast sodium

This classification denotes an anti-asthmatic agent with the molecular formula C35H35ClNO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U1O3J18SFL, chemically known as cyclopropaneacetic acid, 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, monosodium salt but more generally known as montelukast sodium, which bears US NIH Compound Identifier 5281041.

UNSPSC 51161569 Montelukast sodium, a Commodity code, covers the procurement of this leukotriene receptor antagonist medication used primarily to treat asthma and allergy symptoms in state and local health systems, school districts, and public safety agencies. State and local governments purchase montelukast sodium in tablet and chewable formulations as part of pharmaceutical inventories for emergency medical services, school nurse clinics, correctional health programs, and municipal health departments. The medication appears in procurement records as a line item within broader pharmaceutical supply contracts or standalone specialty pharmaceutical purchases.

The source provides no recent state and local contract opportunities tagged to this code. Without posted solicitations or award records, the geographic distribution and issuing-body concentration cannot be characterized from current activity. Business development professionals should monitor this code for activity in state health department cooperative purchasing vehicles and school district health services procurement, where montelukast sodium typically enters procurement cycles as part of seasonal respiratory-illness preparation or ongoing chronic-disease management programs, but current market signals are not available.